logo-loader
Futura Medical PLC

Futura Medical PLC - CSD500: Approval of TTK with Extended Shelf Life

RNS Number : 5974N
Futura Medical PLC
27 October 2016
 

For immediate release                                                                                                    27 October 2016

 

 

 

 

Futura Medical plc

("Futura" or the "Company")

CSD500: Approval of TTK with Extended Shelf Life

Futura Medical plc (AIM: FUM), the innovative healthcare company focused on advanced transdermal technology, is pleased to announce that, as anticipated, its regulatory submission to allow TTK Protective Devices Limited ("TTK") to manufacture CSD500, the Company's novel, erectogenic condom, has been approved by the relevant EU Notified Body with an extended shelf life for the product of 18 months.

TTK, part of the substantial Indian conglomerate TTK Group, is one of Futura's two manufacturing partners for CSD500. In addition to manufacturing CSD500 for worldwide distribution, TTK will also market and distribute CSD500 in India under its SKORE® brand, the fastest growing condom brand in India.

A separate regulatory submission (filed after the TTK submission) for the Company's European manufacturing partner to manufacture CSD500 with the extended shelf life of 18 months is also under review with the same relevant EU Notified Body.  Confirmation will be made in due course as to the outcome of this submission.

James Barder, Futura's Chief Executive, commented: "At the time of our half year results in September, we highlighted that regulatory approval was imminent for TTK to manufacture CSD500 with an extended shelf life of 18 months. This is in line with the requirements of our commercial partners and we are pleased that this approval has now been received.

"Our manufacturing strategy for CSD500 comprises two manufacturing centres: one in Asia and one in Europe. Now that approval for our Asian manufacturer has been received, we will focus on obtaining the approval for our European manufacturer."

For further information please contact:

Futura Medical plc


James Barder, Chief Executive

Tel: +44 (0) 1483 685 670

Email to: james.barder@futuramedical.com

www.futuramedical.com



N+1 Singer (Nominated Adviser and Broker)


Aubrey Powell / Liz Yong

Tel:+44 (0) 20 7496 3000



For media enquiries please contact:


Buchanan


Mark Court / Sophie Cowles / Stephanie Watson

Tel: +44 (0) 20 7466 5000

 

Notes to Editors

Futura Medical plc

Futura Medical is a pharmaceutical group that develops innovative products for consumer healthcare. The Company is developing a portfolio of products and its strategy is to license their manufacture and distribution to major pharmaceutical and healthcare groups.

Futura is based in Guildford, Surrey, and its shares trade on the AIM market of the London Stock Exchange.

www.futuramedical.com

 


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCGUBDGBUDBGLR
NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of...

FOR OUR FULL DISCLAIMER CLICK HERE

Futura Medical marks pivotal year with first meaningful revenue from Eroxon...

Futura Medical PLC (AIM:FUM, OTC:FAMDF) CEO James Barder tells Proactive's Stephen Gunnion that 2023 was a pivotal year for the company as it rolled out its innovative sexual health product, Eroxon, designed to treat erectile dysfunction. The over-the-counter availability of Eroxon distinguishes...

on 7/2/24

3 min read